✦ LIBER ✦

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies

✍ Scribed by Shimada, Muneaki; Fujiwara, Hiroyuki; Sato, Shinya; Oishi, Tetsuro; Itamochi, Hiroaki; Machida, Shizuo; Takei, Yuji; Harada, Tasuku; Suzuki, Mitsuaki; Kigawa, Junzo

Book ID: 113028105
Publisher: Springer
Year: 2012
Tongue: English
Weight: 265 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1885-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I, dose-escalation study of the

A phase I, dose-escalation study of the novel antifolate zd9331 in combination with cisplatin in patients with refractory solid malignancies

✍ J.P. Stevenson; K. Algazy; K. McLaughlin; D.G. Haller; B.J. Giantonio; M. Koehle 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Phase I clinical study of a static magne

Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: Initial safety and toxicity data

✍ Joseph R. Salvatore; Joanne Harrington; Thomas Kummet 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

A phase i/ii study of 166holmium-dotmp i

A phase i/ii study of 166holmium-dotmp in combination with high dose chemotherapy and autologous stem cell transplant(Asct) For the treatment of patients with multiple myeloma(Mm)

✍ W. Bensinger; S. Giralt; J. Eary; D. Podoloff; L. Holmberg; R. Alexanian; M. Goo 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 15 KB

74 Preliminary results of a phase I/II d

74 Preliminary results of a phase I/II dose-escalation study using neoadjuvant chemotherapy and intensity-modulated radiotherapy guided by combined CT and PET imaging in patients with inoperable non-small cell lung cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 142 KB

358 A Multi-arm Phase 1 Dose Escalation

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

✍ Britten, C.; Wainberg, Z.; Tabernero, J.; Alsina Maqueda, M.; Leong, S.; Sessa, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB